Valuation: BioCardia Inc

Market Cap 9.38M 8.15M 7.59M 6.96M 13.15M 895M 13.36M 89.42M 35.09M 446M 35.21M 34.44M 1.49B P/E 2026 *
-1.21x
P/E 2027 * -1.57x
Enterprise Value 9.38M 8.15M 7.59M 6.96M 13.15M 895M 13.36M 89.42M 35.09M 446M 35.21M 34.44M 1.49B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
76.47%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2002
Director of Finance/CFO 62 01/03/2016
Chief Tech/Sci/R&D Officer - 01/08/2017
Director TitleAgeSince
Director/Board Member 59 01/01/2002
Director/Board Member 72 01/01/2011
Chairman 90 01/01/2002
Date Insider Type Main position Quantity % Market Cap.
7/29/26 A Buy

Chief Executive Officer

5,000 0.0440%
7/17/26 A Buy

Chief Executive Officer

500 0.0044%
7/15/26 A Buy

Chief Executive Officer

1,500 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.13%-3.79%+34.48%+157.35% 25.98B
Weighted average by Cap. +0.23%-2.96%+28.67%+119.98%

Financials

2026 *2027 *
Net sales - -
Net income -9.07M -7.89M -7.34M -6.74M -12.73M -866M -12.92M -86.52M -33.96M -431M -34.07M -33.32M -1.45B -10.02M -8.71M -8.1M -7.44M -14.05M -956M -14.27M -95.52M -37.49M -476M -37.61M -36.79M -1.6B
Net Debt - -
Logo BioCardia Inc
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-